SCHEMBL6296282

SCHEMBL6296282

CC(C)(C)c1ccc([N+](=O)[O-])c(NC(=O)C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.52
MAPK1 P28482 3/20 0.52
RAB9A P51151 3/20 0.52
HTT P42858 2/20 0.52
ALDH1A1 P00352 2/20 0.52
GLA P06280 1/20 0.52
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
PDK1 Q15118 2/20 0.51
PDK2 Q15119 2/20 0.51
PDK3 Q15120 2/20 0.51
PDK4 Q16654 2/20 0.51
AR P10275 4/20 0.48
AKR1B1 P15121 1/20 0.46
AKR1C4 P17516 1/20 0.46
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29451808 0.83 PDK1 (0.50) ALDH1A1PDK1PDK2PDK3PDK4
SCHEMBL8936699 0.80 MAPT (0.51) MAPK1ALDH1A1PDK1PDK2PDK3
SCHEMBL6303134 0.80 PDK1 (0.47) MAPK1HTTALDH1A1GLAPDK1
SCHEMBL19022324 0.79 MEN1 (0.43) NPC1MAPK1RAB9AHTTALDH1A1
SCHEMBL29659895 0.77 KCNMA1 (0.63) NPC1MAPK1RAB9AHTTALDH1A1
SCHEMBL22262383 0.77 KCNMA1 (0.63) NPC1MAPK1RAB9AHTTALDH1A1
SCHEMBL2554351 0.77 RECQL (0.52) NPC1MAPK1RAB9AHTTALDH1A1
SCHEMBL5103222 0.76 PDK1 (0.71) NPC1RAB9AALDH1A1PDK1PDK2
SCHEMBL30093275 0.76 PDK1 (0.71) NPC1RAB9AALDH1A1PDK1PDK2
SCHEMBL9762475 0.75 NPSR1 (0.47) MAPK1HTTALDH1A1GLAPDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6852711-B2 Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for AGOURON PHARMACEUTICALS, INC. (US) 2005-02-08 US disclosed
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP disclosed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD NPC1 787/4885MAPK1 2780/4885RAB9A 3077/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD NPC1 754/4885MAPK1 2779/4885RAB9A 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.